Anzeige
Mehr »
Login
Samstag, 21.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Breaking News: Vorweihnachtlicher Kaufrausch an der Börse?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853849 | ISIN: JP3463000004 | Ticker-Symbol: TKD
Tradegate
20.12.24
18:18 Uhr
25,320 Euro
+0,140
+0,56 %
Branche
Chemie
Aktienmarkt
NIKKEI-225
Singapur
1-Jahres-Chart
TAKEDA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
TAKEDA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
24,95025,35012:25
25,05025,30020.12.

Aktuelle News zur TAKEDA PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoTakeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative5
MiTakeda casts a new line with first DTC campaign for HyQvia in CIDP5
MiTAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::AMENDMENT EXTRAORDINARY REPORT3
TAKEDA PHARMACEUTICAL Aktie jetzt für 0€ handeln
13.12.IN BRIEF: Hutchmed to get Takeda milestone payment4
13.12.TAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer1
13.12.Hutchmed to receive $10m milestone payment from partner Takeda3
13.12.HUTCHMED To Get 10 Mln Milestone Payment From Takeda For First European Reimbursement For FRUZAQLA270BEIJING (dpa-AFX) - HUTCHMED (China) Limited (HCM) Friday said it will receive a milestone payment of $10 million from Takeda Pharmaceutical Company Limited (TAK) after Takeda received a national...
► Artikel lesen
13.12.Hutchmed China Ltd - HUTCHMED to Receive Milestone Payment from Takeda1
13.12.HUTCHMED (China) Limited: HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA (fruquintinib)181- US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe - - Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy...
► Artikel lesen
13.12.TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::TAKEDA R&D DAY 20241
09.12.Teva divests from Japanese JV with Takeda32
06.12.Teva, Takeda sell generics joint venture in Japan to focus on innovative drugs30
06.12.Teva to divest Teva-Takeda business venture in Japan to JKI18
06.12.Teva Pharma To Divest Teva-Takeda Business Venture In Japan To JKI737PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) announced that it will divest Teva-Takeda, its business venture in Japan, to JKI Co., Ltd. The divestment, which includes generics...
► Artikel lesen
06.12.Teva Pharmaceutical Industries Ltd: Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan630Teva entered into an agreement with JKI Co., Ltd. ("JKI") established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. ("J-Will"), through which JKI will acquire Teva-TakedaThe...
► Artikel lesen
04.12.Takeda, Keros Enter Exclusive Elritercept Agreement9
04.12.Takeda licensed for anaemia therapy by Keros Therapeutics13
03.12.Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood Cancers and Beyond6
03.12.Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst14
03.12.Takeda in licensing agreement with Keros over elritercept5
Seite:  Weiter >>
201 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1